Literature DB >> 12700635

Silencing of death receptor and caspase-8 expression in small cell lung carcinoma cell lines and tumors by DNA methylation.

S Hopkins-Donaldson1, A Ziegler, S Kurtz, C Bigosch, D Kandioler, C Ludwig, U Zangemeister-Wittke, R Stahel.   

Abstract

Small cell lung cancer cell lines were resistant to FasL and TRAIL-induced apoptosis, which could be explained by an absence of Fas and TRAIL-R1 mRNA expression and a deficiency of surface TRAIL-R2 protein. In addition, caspase-8 expression was absent, whereas FADD, FLIP and caspases-3, -7, -9 and -10 could be detected. Analysis of SCLC tumors revealed reduced levels of Fas, TRAIL-R1 and caspase-8 mRNA compared to non-small cell lung cancer (NSCLC) tumors. Methylation-specific PCR demonstrated methylation of CpG islands of the Fas, TRAIL-R1 and caspase-8 genes in SCLC cell lines and tumor samples, whereas NSCLC samples were not methylated. Cotreatment of SCLC cells with the demethylating agent 5'-aza-2-deoxycytidine and IFNgamma partially restored Fas, TRAIL-R1 and caspase-8 expression and increased sensitivity to FasL and TRAIL-induced death. These results suggest that SCLC cells are highly resistant to apoptosis mediated by death receptors and that this resistance can be reduced by a combination of demethylation and treatment with IFNgamma.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12700635     DOI: 10.1038/sj.cdd.4401157

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  71 in total

Review 1.  Resistance to TRAIL and how to surmount it.

Authors:  Danijela Maksimovic-Ivanic; Stanislava Stosic-Grujicic; Ferdinando Nicoletti; Sanja Mijatovic
Journal:  Immunol Res       Date:  2012-04       Impact factor: 2.829

2.  Paclitaxel and TRAIL synergize to kill paclitaxel-resistant small cell lung cancer cells through a caspase-independent mechanism mediated through AIF.

Authors:  Terri B Hunter; Neil J Manimala; Kimberly A Luddy; Tracy Catlin; Scott J Antonia
Journal:  Anticancer Res       Date:  2011-10       Impact factor: 2.480

Review 3.  In search of tumor suppressing functions of menin.

Authors:  Yuqing Yang; Xianxin Hua
Journal:  Mol Cell Endocrinol       Date:  2007-01-11       Impact factor: 4.102

4.  The Deubiquitinase Inhibitor PR-619 Sensitizes Normal Human Fibroblasts to Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL)-mediated Cell Death.

Authors:  Roslyn N Crowder; David T Dicker; Wafik S El-Deiry
Journal:  J Biol Chem       Date:  2016-01-12       Impact factor: 5.157

5.  Menin-mediated caspase 8 expression in suppressing multiple endocrine neoplasia type 1.

Authors:  Ping La; Yuqing Yang; Satyajit K Karnik; Albert C Silva; Robert W Schnepp; Seung K Kim; Xianxin Hua
Journal:  J Biol Chem       Date:  2007-08-31       Impact factor: 5.157

6.  Synergistic targeting of AML stem/progenitor cells with IAP antagonist birinapant and demethylating agents.

Authors:  Bing Z Carter; Po Yee Mak; Duncan H Mak; Yuexi Shi; Yihua Qiu; James M Bogenberger; Hong Mu; Raoul Tibes; Hui Yao; Kevin R Coombes; Rodrigo O Jacamo; Teresa McQueen; Steven M Kornblau; Michael Andreeff
Journal:  J Natl Cancer Inst       Date:  2014-02       Impact factor: 13.506

Review 7.  Epigenetic mechanisms of tumor resistance to immunotherapy.

Authors:  Natalia Arenas-Ramirez; Dilara Sahin; Onur Boyman
Journal:  Cell Mol Life Sci       Date:  2018-08-23       Impact factor: 9.261

8.  Evasion of apoptosis as a cellular stress response in cancer.

Authors:  Simone Fulda
Journal:  Int J Cell Biol       Date:  2010-02-18

9.  Analysis of death receptor 5 and caspase-8 expression in primary and metastatic head and neck squamous cell carcinoma and their prognostic impact.

Authors:  Heath A Elrod; Songqing Fan; Susan Muller; Georgia Z Chen; Lin Pan; Mourad Tighiouart; Dong M Shin; Fadlo R Khuri; Shi-Yong Sun
Journal:  PLoS One       Date:  2010-08-16       Impact factor: 3.240

10.  Doxorubicin and etoposide sensitize small cell lung carcinoma cells expressing caspase-8 to TRAIL.

Authors:  Alena Vaculova; Vitaliy Kaminskyy; Elham Jalalvand; Olga Surova; Boris Zhivotovsky
Journal:  Mol Cancer       Date:  2010-04-23       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.